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ABSTRACT 
Combretastatin A-4 (CA-4) represents one of the most promising 
antineoplastic and cancer vascular targeting stilbenes that have been isolated from 
the South African bush willow, Combretum Caffrum Kuntze.  In order to further 
explore the bioactivity of this molecule, a diiodo derivative of CA-4, as well as its 
phosphate prodrug, was synthesized and analyzed for its biological activity; 
although only a scale up synthesis of this compound was performed herein for 
ongoing analysis.  In general, no increased specificity was noted for the human 
cancer cell lines.  Antiangiogenic properties were similar to the untreated control.  
The diiodocombstatin was active against M. luteus, and its phosphate prodrugs 
were very active against N. gonorrhoeae.   
Combretastain A-2 is another biologically active stilbene isolated from 
Combretum Caffrum Kuntze.  In an attempt to increase biological activity of this 
molecule both mono-iodo and diiodo derivatives have been partially synthesized.  
The initial step involving the iodination of piperonal utilizes a novel, cost 
effective and mild reaction.  The iodo stilbenes were obtained via a Wittig 
reaction using phosphonium salts 25 and 27 along with 2,3-Bis-[tert-
butyldimethylsiloxy]-4-methoxy benzaldehyde 29.  Deprotection of the 
subsequent z-stilbenes, non-isolated mono-iodo stilbene and the diiodo 30 
produced two synthetic objective z-stilbenes 16 and 17.  Synthesis as well as 
biological analysis is ongoing.   
 
 
ii 
 
ACKNOWLEDGEMENTS 
 I want to express my deep gratitude to Dr. G.R. Pettit for taking me on as 
a master’s student and providing ongoing support while I studied and performed 
research.  I am grateful to Dr. R. Dixon for teaching me laboratory techniques, to 
Drs. F. Hogan and C. Herald for constantly answering questions and keeping 
funds open for use.  I want to thank Dr. J-C. Chapius for his biological 
evaluations, and Dr. J.C. Knight and Natasha Zolotov for their mass spec 
expertise.  I am thankful to have worked with Dr. C. Pruis and to have received 
her support as well as the Chemistry Department’s support while I studied at 
ASU.  I am grateful to Drs. E. Skibo and A. Moore for their willingness to work 
with me on my committee and their support in obtaining a degree so much later 
than intended.  I am aslo appreciative of the help that M. Mcdowell and T. 
Thornburgh have readily offered me in finishing this endeavor.  I especially want 
to thank Dr. N. Melody for her constant mentoring throughout my stay at ASU as 
well as her generous friendship; without her, I would not have been able to 
complete the master’s program.   
 I am also grateful for my husband and children and their patience through 
this very long process. 
 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
Page 
LIST OF TABLES………………………………………………………….…….v 
LIST OF FIGURES……………………………………………………………...vi 
LIST OF SCHEMES…………………………………………………………....viii 
Chapter  
1 
CANCER AND NATURAL PRODUCTS...……………….......................1 
 Cancer in the United States..............................................................1 
Natural Products’ Contribution to Medicine....................................4 
References      
2 COMBRETUM CAFFRUM......................................................................15 
Brief History of the Combretastatins.............................................15 
Combretastatin Structure Activity Relationships...........................18 
References        
3 SCALE-UP SYNTHESIS OF THE ANTINEOPLASTIC AGENT 
SODIUM 3,5-DIIODO-4,4’-DIMETHOXY-Z-STILBENE 3’-O-
 PHOSPHATE................................................................................22 
  Introduction....................................................................................22 
  Results and Discussion..................................................................23 
  Conclusions....................................................................................26 
  Materials and Methods...................................................................26 
 
 
iv 
 
CHAPTER                       Page 
  Experimental..................................................................................27 
  References                 
4 IODINATION OF PIPERANOL...............................................................33 
  Introduction....................................................................................33 
  Solvent Directed Electrophilic Aromatic Substitution..................34 
  Attempts to Drive the Reaction Towards the Mono-iodo  
   Product (21) and the Diiodinated Product (22)..................36 
   Summary........................................................................................39 
  Experimental..................................................................................39 
  References        
5  PARTIAL SYNTHESIS AND BIOLOGICAL EVALUATION OF THE  
  ANTINEOPLASTIC AGENT 5-IODO-3,4-    
  METHYLENEDIOXY-2’,3’-DIHYDROXY-4’-METHOXY-Z- 
  STILBENE (16) and 2,5-DIIODO-3,4-METHYLENEDIOXY- 
  2’,3’-DIHYDROXY-4’-METHOXY-Z-STILBENE (17).............44           
  Introduction....................................................................................44 
  Results and Discussion..................................................................44 
  Conclusions....................................................................................48 
  Materials and Methods...................................................................49 
  Experimental..................................................................................50 
  References        
 
 
v 
 
LIST OF TABLES 
 
Table               Page 
1.1 Estimated U.S. Cancer Cases.......................................................................1 
1.2 U.S. Cancer Mortality, 2006........................................................................2 
1.3 Lifetime Probability of Developing Cancer, Men/Women, U.S., 
  2003-2005........................................................................................2 
1.4 Trends in Five-year Relative Survival (%) Rates, U.S., 1975-2004............3 
5.1 Cancer Cell Biology for 5-iodo-3,4-methylenedioxy- 
  benzaldehyde (21) and 2,5-diiodo-3,4-methylenedioxy- 
  benzaldehyde (22)..........................................................................45 
5.2 Cancer Cell Biology for 5-iodo-4-methoxy-3,4-methylenedioxy- 
2’,3’-dihydroxy-stilbenes and 2,5-diiodo-4’-methoxy-3,4-
methylene-dioxy-2’,3’-O-tert-butyl-dimethylsilyl-stilbenes.........48 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
LIST OF FIGURES 
Figure              Page 
1.1 Quinine.........................................................................................................4 
1.2 Quinidine......................................................................................................4 
1.3 Cinchona Tree..............................................................................................4 
1.4 Physostigmine..............................................................................................4 
1.5 Neostigmine.................................................................................................4 
1.6 Calabar Bean................................................................................................5 
1.7 Paclitaxel......................................................................................................5 
1.8 Pacific Yew Tree..........................................................................................6 
1.9 Colchicine....................................................................................................6 
1.10 Meadow Saffron...........................................................................................7 
1.11  Morphine......................................................................................................8 
1.12 Opium Poppy Plant......................................................................................8 
1.13 Core Structure of Penicillin.........................................................................8 
1.14 Penicillium Fungi.........................................................................................9 
1.15 Combretastatin A-4 Phosphate (CA4P) (1)...............................................10 
1.16 Combretastatin A-1 Phosphate (CA1P) (2)...............................................10 
1.17 Combretastatin A-4 (1a)............................................................................10 
1.18 Combretastatin A-1 (2a)............................................................................10  
 
2.1 (-)-Combretastatin (3)................................................................................15  
 
2.2 Combretastatin A-series (2a-f)...................................................................16  
 
2.3 Combretastatin B-series (3a-d)..................................................................17 
vii 
 
 
Figure              Page 
 
2.4 Combretastatin C-1 (4)..............................................................................17  
 
2.5 Combretastatin D-series (5a-b)..................................................................18  
 
3.1 Sodium 3,5-diiodo-4,4’ dimethoxy-z-stilbene 3’-O-phosphate (15).........23 
4.1 Combretastatin A-2 (CA-2).......................................................................33 
4.2 CA-2 Phosphate Prodrug...........................................................................33 
4.3 Mono-iodo Derivative of CA-2 (16)..........................................................34 
4.4 Diiodo Derivative of CA-2 (17).................................................................34 
4.5 Mono-iodo Derivative of CA-2 Prodrug (18)............................................34 
4.6 Diiodo Derivative of CA-2 Prodrug (19)...................................................34  
4.7 Piperonal (20).............................................................................................34 
4.8 [Bis(trifluoroacetoxy)iodo]benzene (BTI).................................................35 
4.9 3-Iodo-piperanol (21).................................................................................35 
4.10 2,5-Diiodo-piperanol (22)..........................................................................35 
4.11 2,3-Diiodo-piperanol (23)..........................................................................38  
 
 
 
 
 
 
 
 
viii 
 
 
LIST OF SCHEMES 
Scheme             Page 
3.1 Synthesis of Phosphonium Bromide (9)....................................................24 
3.2 Synthesis of Diiodo Benzaldehyde (11)....................................................24        
3.3 Synthesis of 2,4-Bismethyl-2,4-diiodo-CA4P (15)...................................25 
5.1 Mono-iodination of Piperonal, Reduction and Conversion to Phosphonium 
  Bromide (25)..................................................................................46 
5.2 Diiodination of Piperonal, Reduction and Conversion to Phosphonium  
  Bromide (27)..................................................................................46 
5.3 Synthesis of the Protected B-ring (29).......................................................47 
5.4 Synthesis of 4,5-Bismethyl-3-iodo-CA-2 (16)..........................................47 
5.5 Synthesis of 3,4-Bismethyl-2,5-diiodo-CA-2 (17)....................................48 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1 
 
Cancer and Natural Products 
 
1.1  Cancer in the United States 
 Cancer is a growing pandemic in the world.  The American Cancer 
Society estimates that there will be 1.5 million (Table 1.1) new cases of cancer 
diagnosed within the United States alone in 2009.
1
   
Table 1.1 Estimated U.S. Cancer Cases* 
Cancer Type Men Cancer Type Women 
Prostate 25% Breast 27% 
Lung & bronchis 15% Lung & bronchis 14% 
Colon & rectum 10% Colon & rectum 10% 
Urinary bladder 7% Uterine corpus 6% 
Melanoma of skin 5% Non-Hodgkin lymphoma 4% 
Non-Hodgkin lymphoma 5% Melanoma of skin 4% 
Kidney & renal pelvis 5% Thyroid 4% 
Leukemia 3% Kidney & renal pelvis 3% 
Oral cavity 3% Ovary 3% 
Pancreas 3% Pancreas 3% 
All Other Sites 19% All Other Sites 22% 
Estimated Number 766,130 Estimated Number 713,220 
*Estimates prepared by the American Cancer Society and do not include basal 
and squamous cell skin cancers and in situ carcinomas except urinary bladder.
1
 
 
In 2006, cancer accounted for close to one-quarter of the deaths in the U.S. and 
was exceeded only by heart disease (Table 1.2).
1
 The probability of an American 
man developing cancer is one in two while the probability of an American woman 
developing cancer is one in three (Table 1.3).
1
  Despite these discouraging 
2 
 
numbers, cancer survival rates are increasing
1 
(Table 1.4) due to the progress in 
early detection as well as the progress in treatment.
2
    
Table 1.2 U.S. Mortality, 2006 
Rank Cause of Death No. of Deaths % of all Deaths 
1. Heart Diseases 631,636 26.0 
2. Cancer 559,888 23.1 
3. Cerebrovascular diseases 137,119 5.7 
4. Chronic lower respiratory diseases 124,583 5.1 
5. Accidents (unintentional injuries) 121,599 5.0 
6. Diabetes mellitus 72,449 3.0 
7. Alzheimer disease 72,432 3.0 
8. Influenza & pneumonia 58,326 2.3 
9. Nephritis* 45,344 1.9 
10. Septicemia 34,234 1.4 
*Includes Nephrote syndrome and nephrosis. 
Source: U.S. Mortality Data 2006, National Center for Health Statistics, Center 
for Disease Control and Prevention, 2009. 
 
Table 1.3 Lifetime Probability of Developing Cancer, Men/Women, US, 
2003-2005* 
Site in Men Risk Site in Women Risk 
All Sites+ 1 in 2 All Sites+ 1 in 3 
Prostate 1 in 6 Breast 1 in 8 
Lung and bronchus 1 in 13 Lung & bronchus 1 in 16 
Colon and rectum 1 in 18 Colon & rectum 1 in 20 
Urinary bladder
 1 in 27 Uterine corpus 1 in 40 
Melanoma
 1 in 39 Non-Hodgkin lymphoma 1 in 53 
Non-Hodgkin lymphoma 1 in 45 Urinary bladder
 1 in 84 
Kidney 1 in 57 Melanoma
 1 in 58 
Leukemia 1 in 67 Ovary 1 in 72 
Oral Cavity 1 in 72 Pancreas 1 in 75 
Stomach 1 in 90 Uterine cervix 1 in 145 
*For those free of cancer at beginning of age interval. 
+All sites exclude basal and squamous skin cancers and in situ cancers except 
urinary bladder. 

Includes invasive and in situ cancer cases. 

Statistics for white men and women. 
Source: DevCan: Probability of Developing or Dying of Cancer Software, 
Version 6.3.0 Statistical Research and Applications Branch, NCI, 2008. 
http://srab.cancer.gov/devcan 
 
3 
 
Table 1.4 Trends in Five-year Relative Survival (%)* Rates, US, 1975-2004 
Site 1975-1977 1984-1986 1996-2004 
All sites 50 54 66 
Breast (female) 75 79 89 
Colon 52 59 65 
Leukemia 35 42 51 
Lund and bronchus 13 13 16 
Melanoma 82 87 92 
Non-Hodgkin lymphoma 48 53 65 
Ovary 37 40 46 
Pancreas 3 3 5 
Prostate 69 76 99 
Rectum 49 57 67 
Urinary bladder 74 78 81 
*5-year relative survival rates based on follow up patients through 2005. 
Source: Surveillance, Epidemiology, and End Results Program, 1975-2005, 
Division of Population Sciences, National Cancer Institute, 2008. 
 
1.2 Natural Products’ Contribution to Medicine  
 Natural products have played an extraordinarily valuable role in the drug 
discovery process.  Some examples of natural products that have made a major 
impact on modern medicine include but are not limited to: quinidine, quinine, 
physostigmine, neostigmine, paclitaxel, colchicine, morphine, codeine and 
penicillin.  Quinine (Figure 1.1) was isolated from the bark of the Cinchona tree 
and was one of the first anti-infective agents due to its efficacy against malaria.
3  
Quinidine (Figure 1.2) is the diastereoisomer of quinine and is an important anti-
arrhythmic drug.
3
   
 
4 
 
                      
   Figure 1.1 Quinine synthesis, 1944
4
         Figure 1.2 Quinidine synthesis, 1978
5
 
 
Figure 1.3 Cinchona Tree
6
 
 Physostigmine (Figure1.4) is a naturally occurring alkaloid isolated from 
the calabar bean (Figure 1.6) and Neostigmine (Figure 1.5) is its synthetic analog; 
both are important acetylcholinesterase inhibitors.
7
   
                          
             Figure 1.4 Physostigmine
7
       Figure 1.5 Neostigmine
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Figure 1.6 Calabar Bean
8
 
 Paclitaxel (Figure 1.7) is an unaltered natural product isolated from the 
Pacific yew tree (Figure 1.8) whose mechanism of derivation blocks de-
polymerization of microtubules and is commonly used to treat ovarian, breast, 
lung, and colon cancer.
9 
 
Figure 1.7 Paclitaxel
9
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Figure 1.8 Pacific Yew Tree
9
 
 Colchicine (Figure 1.9) was isolated from the Meadow Saffron (Figure 
1.10) and is commonly used to treat gout and familial Mediterranean fever.
3 
 
Figure 1.9 Colchicine, 1820
10
 
 
O
H3CO
H3CO
OCH3
OCH3
NH
O
7 
 
 
Figure 1.10 Meadow Saffron
11
 
 Morphine (Figure 1.11) was the first active alkaloid extracted from the 
opium poppy plant (Papaver somnifer) (Figure 1.12).
12
  It acts directly on the 
central nervous system to relieve pain, therefore it is used as an analgesic 
psychoactive drug.
3
  Codeine (Figure 1.11) was also isolated from the opium 
poppy plant but is more commonly synthesized from O-methylation of morphine.
3
  
Codeine is commonly used to treat a cough, diarrhea, mild to severe pain, and 
irritable bowel syndrome.
3
   
 
8 
 
                                           
Figure 1.11 Morphine R=H, Codeine R=CH3
12
 Figure 1.12 Opium Poppy Plant
12 
 Penicillin (Figure 1.13) is the active constituent isolated from Penicillium 
fungus (Figure 1.14).
3
  This discovery led to a dramatic change in medical history 
with the introduction of antibiotics.  Antibiotics have had a huge impact on life 
expectancy as well as on quality of life.  They play an important role as drugs in 
modern medicine and have also helped scientists understand the mechanisms by 
which these natural products exert their action.  This biological understanding has 
allowed for the targeting of pathogens that would not likely have been possible 
without these biochemical probes.
3
 
 
Figure 1.13 Core Structure of Penicillin
13
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Figure 1.14 Penicillium Fungi
14
 
 Studies taken in 1996 revealed that over 60% of the approved drugs and 
pre-NDA candidates, excluding biologics, for anticancer and antiinfective agents 
from 1984-1995 are of natural origin.  62% of the 87 approved anticancer drugs 
are of natural origin or are modeled after natural product parents.  50 of the 299 
pre-NDA anticancer drug candidates are the original natural product, while 48 are 
semisynthetic derivatives, and 30 are based on natural product models.  Seven of 
the 93 new approved antiinfectives are natural products, 45 are semisynthetic 
derivatives, and seven are based on natural product models.  This means that 63% 
of the approved antiinfectives are of natural origin.
15
   
 A more recent study, taken in 2006, showed that 63 of 81 anticancer drugs 
were either natural products or mimicked natural products in some form.  The 
same study showed that ~50% of all small molecules approved as “New Chemical 
Entities” in the years 2000-2006 were derived from the natural products.16 
 The anticancer drugs Combretastatin A-4 phosphate 1 (CA4P) (Figure 
1.15) and Combretastatin A-1 phosphate 2 (CA1P) (Figure 1.16) are two such 
NCEs.  CA4P is the first well-established vascular-targeting anticancer drug.
17
  
10 
 
CA4P was synthesized
18
 from combretastatin A-4 1a (Figure 1.17) which was 
isolated from the South African bushwillow, Combretum Caffrum Kuntze.
19
  
CA1P was likewise synthesized
20
 from combretastatin A-1 2a (Figure 1.18) 
which was also isolated from Combretum Caffrum Kuntze.
21
      
 
Figure 1.15 Combretastatin A4P       Figure 1.16 Combretastatin A1P 
               
    Figure 1.17 Combretastatin A-4                     Figure 1.18 Combretastatin A-1 
 The South African bush willow, Combretum Caffrum Kuntze, has been the 
source of many biologically active compounds.
17
  Combretastatin A-4P 
(ZYBRESTAT) has had success in phase II/III clinical trials evaluating the safety 
and efficacy of CA4P in combination with Paclitaxel and Carboplatin in 
comparison with Paclitaxel and Carboplatin against Anaplastic Thyroid 
Carcinoma.
22
  CA4P is also involved in clinical trials as a treatment for solid 
tumors.
23
  Combretastatin A-1 phosphate (OXi4503) is currently involved in 
H3CO
OCH3
H3CO
OCH3 O P
O
O
O Na
Na
1
H3CO
OCH3
H3CO
OCH3 OH
1a
H3CO
OCH3
H3CO
OCH3 OH
OH
2a
11 
 
dose-escalating phase I and phase II studies evaluating its safety when 
administered to patients with advanced solid tumors.
24
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Chapter 2 
 
Combretum Caffrum 
 
2.1 Brief History of the Combretastatins 
 African traditional medicine utilizes some 24 species of the Combretum 
genus.
1
  These plants are used to treat problems ranging from heart and worm 
remedies, to wound dressings, treatment for the mentally ill, scorpion stings
2
, 
leprosy, and even cancer.
3
  However, it was not until the 1970s that the United 
States National Cancer Institute (NCI), during its worldwide exploratory survey 
of plants, found that the root bark of the South African willow tree Combretum 
Caffrum had significant activity against the murine P388 lymphatic leukemia 
(ED50 0.011 ug/mL).
4
  Dr. G.R. Pettit and colleagues later isolated (using an 
astrocytoma bioassay procedure) the cancer cell growth inhibitor (-)-
combretastatin (Figure 2.1) from C. Caffrum.
5,6
   
H3CO
OCH3
H3CO
OCH3 OH
OH
3  
Figure 2.1 (-)-Combretastatin 
 (-)-Combretastatin (3) caused a significant rise in the mitotic index of 
L1210 cells, inhibited tubulin polymerization (IC50 5-7 uM), stimulated tubulin-
16 
 
dependent GTP hydrolysis, and competitively inhibited the binding of colchicines 
to tubulin [34% binding by colchicines in the presence of 3 (1:1 concentration 
ratio)].
7
  The isolation and synthesis of (-)-combretastatin led our research group 
to isolate twenty related substances within what is now considered the 
combretastatins.  The combretastatins consist of a group of stilbenes called the A-
series (Figure 2.2),
8-11
 four bibenzyl compounds called the B-series (Figure 2.3),
8, 
9, 12
 a phenanthraquinone called combretastatin C-1 (Figure 2.4),
13
 and 
macrocyclic lactones called combretastatin D-1 and D-2 (Figure 2.5).
14, 15
  
              
2a, R1 = OH, R2 = H, R3 = R4 = CH3, A-1   2f, A-6  
P388 ED50 = 0.99 ug/mL; tubulin IC50 = 2-3 uM.
8
  P388 ED50 = 18 ug/mL;
16
  
2b, R1 = R2 = H, R3 = R4 = -CH2-, A-2   tubulin IC50 > 100 uM.
17 
P388 ED50 = 0.027 ug/mL; tubluin IC50 = 4-5 uM.
9
 
2c, R1 = R2 = H, R3 = CH3, R4 = H, A-3 
P388 ED50 = 0.026 ug/mL; tubulin IC50 = 4-5 uM.
9 
2d, R1 = R2 = H, R3 = R4 = CH3, A-4 
P388 ED50 = 0.0034 ug/mL; tubulin IC50 = 2-3 uM.
10
 
2e, R1 = H, R2 = R3 = CH3, R4 = H, A-5 
P388 ED50 = 0.9 ug/mL;
11
 tubulin IC50 = 75-100 uM.
16
 
Figure 2.2 Combretastatin A-Series 
R4O
R3O
OCH3
OCH3
OR2
R1 HO
H3CO
OCH3
OCH3
OCH3
17 
 
 
3a, R1 = OH, R2 = H, R3 = CH3, R4 = R5 = OCH3, B-1 
P388 ED50 = 2.7 ug/mL.
8
 
3b, R1 = R2 = H, R3 = CH3, R4 = OCH3, R5 = OH, B-2 
P388 ED50 = 0.32 ug/mL;
9
 tubulin IC50 = 40 uM.
16 
3c, R1 = R2 = R3 = H, R4 = R5 = OCH3, B-3 
P388 ED50 = 0.4 ug/mL;
12
 tubulin IC50 > 100 uM.
16
 
3d, R1 = R2 = R3 = R4 = H, R5 = OCH3, B-4 
P388 ED50 = 1.7 ug/mL;
12
 tubulin IC50 > 100 uM.
16
 
Figure 2.3 Combretastatin B-Series 
 
Figure 2.4 Combretastatin C-1 
P388 ED50 = 2.2 ug/mL.
13
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  5a, D-1    5b, D-2 
Figure 2.5 Combretastatin D-Series 
P388 ED50 = 3.3 ug/mL.
14
  P388 ED50 = 5.2 ug/mL.
15
 
 
Chapter 2.2 Combretastatin Structure Activity Relationships 
 Due to the simplicity of structure, relative simplicity of synthesis, and 
potency of the combretastatins, many derivatives have been synthesized and 
structure activity relationships been characterized.  As the previous figures show, 
any major deviations from the original natural product resulted in a drop in 
cytotoxicity.  The trans-stilbene also displays lower activity than the cis-stilbene.  
A very important discovery showed that the phosphate prodrug showed an 
increase in water solubility over the natural compound.
18
 
 The combretastatin series has produced many biologically active 
compounds.  The ongoing SARS studies have helped scientists locate the 
necessary configurations and groups for increasing this activity.  Combretastatin 
A-4P (1) is the most biologically promising stilbene isolated from C. caffrum.
11, 19, 
20
  It has proven to be a potent tubulin polymerization inhibitor, human cancer cell 
line inhibitor, and an effective vascular targeting agent.
11, 19, 20
  Combretastatin A-
1P (2) is also a very biologically promising stilbene.
20
  Both are part of ongoing 
clinical trials for use as anticancer drugs.
21, 22
  This success continues to promote 
O
OH
O
O
O
O
OH
O
O
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the study of the combretastatin compounds and their derivatives as well as drive 
new synthesis of novel derivatives.   
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Chapter 3 
 
Scale-up Synthesis of the Antineoplastic Agent Sodium 3,5-diiodo-
4,4’dimethoxy-Z-stilbene 3’-O-phosphate 
 
3.1 Introduction 
 The South African bush willow, Combretum Caffrum Kuntze, has been the 
source of many biologically active compounds.  In collaboration with the NCI 
Natural Products Branch, Dr. G.R. Pettit and his research group continued a series 
of investigations of chemical constituents from the C. Caffrum collection.
1
  This 
pursuit eventually led to the discovery of the Combretastatins, and more 
specifically the discovery of Combretastatin A-4 (1a).
2
  Combretastatin A-4 is the 
most biologically promising stilbene isolated from C. Caffrum.  It has proven to 
be a potent tubulin polymerization inhibitor, human cancer cell line inhibitor, and 
an effective vascular targeting agent.
1-3
   Due to the success of Combretastatin A-
4 in phase II clinical trials,
4 
many structure activity relationship syntheses have 
been and continue to be pursued.  This particular SAR study is based on the fact 
that CA4P (the phosphate prodrug of CA-4) had sufficient activity against thyroid 
cancer during phase I clinical trials.
5
  The National Cancer Institute estimates that 
in 2007, there will be 33,550 new cases of thyroid cancer and 1,530 deaths due to 
thyroid cancer.
6
  Papillary and follicular carcinoma are the major types of 
carcinoma of the thyroid gland while medullary (neuroendocrine) and anaplastic 
(very aggressive) are less common.
5
  It has been found that both follicular and 
23 
 
anaplastic carcinomas are more common in populations residing in an area 
deficient in iodine.
5
  In order to enhance the activity of CA-4P in thyroid 
carcinoma tissue, a diiodo structural (Figure 3.1) modification has been targeted 
for synthetic and biological evaluation. 
 
Figure 3.1 Sodium 3,5-diiodo-4,4’dimethoxy-Z-stilbene 3’-O-phosphate 
3.2 Results and Discussion 
 The target compound was synthesized using a wittig reaction sequence 
with 3,5-diiodo-4-methoxy-benzaldehyde (11) with 3-O-tert-butyldiphenylsiloxy-
4-methoxy-benzaldehyde (9).
6
  Deprotection with tetrabutylammonium fluoride 
yielded the diiodo-stilbene (13).  The phosphate group was introduced to the Z-
isomer (12) using dibenzyl phosphate and carbon tetrachloride in the presence of 
diisopropylthylamine, N,N-dimethylaminopyridine to provide bisbenzylphosphate 
(14).  The benzyl protecting group was then cleaved using bromotrimethylsilane 
and the resulting phosphoric acid was treated with sodium methoxide to yield the 
prodrug (15).     
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NaO P
O
O
O
H3CO
OCH3
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I
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Scheme 3.1 Synthesis of Phosphonium Bromide (9) 
 
 
 
Scheme 3.2 Synthesis of Diiodo Benzaldehyde (11) 
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Scheme 3.3 Synthesis of 3,5-diiodo-3,4’-dimethoxy-Z-stilbene 3’-O-phosphate 
(15) 
 
 
 
 
 
 
 
 
*The E/Z isomers were separated via column chromatography.  
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3.3 Conclusions  
 The scale up synthesis was straight forward and the reaction sequence was 
based on one as described by Dr. Heidi Rosenburg.
5
 Recrystallization techniques 
needed to be improved for purification and to obtain better NMR data.  In several 
cases the 
1
H-NMR data was slightly different than the literature shifts and the 
coupling constants varied slightly as well.  Further scale-up and purification is 
needed in order for biological testing to continue.     
3.4 Materials and Methods 
 Isovanillin, anhydrous dicholoromethane (DCM), anhydrous toluene, 
dibenzylphosphite, triphenylphosphine, iodomethane, and carbon tetrachloride 
were obtained from Sigma-Aldrich Chemical Company (Milwaukee, WI).  3,5-
diiodo-4-hdroxybenzaldehyde was purchased from Lancaster Synthesis Inc. 
(Windham, NH).  Diisopropylethylamine was obtained from Avocado Alfa Aesar 
(Ward Hill, MA).  All other reagents were purchased from Acros Organics (Fisher 
Scientific, Pittsburg, PA).   
 All reactions were monitored by thin-layer chromatography using 
Analtech silica gel GHLF Uniplates visualized under long-wave and short-wave 
UV irradiation and by dipping into phosphomlybic acid in ethanol followed by 
heating.  Solvent extracts of aqueous solutions were dried over anhydrous 
magnesium sulfate.  Where appropriate, the crude products were separated by 
column chromatography, flash (230-400 mesh ASTM) or gravity (70-230 mesh 
ASTM) silica from E. Merck. 
 Melting points were measured using an electrothermal digital melting 
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point apparatus and are uncorrected.  All 1H- and 13C-NMR spectra were 
obtained using Varian Gemini 300 MHz or varian unity 400 or 500 MHz 
instruments with CDCl3 (tetramethylsilane internal reference) as solvent unless 
otherwise noted.  Elemental analyses were determined by Galbraith Laboratories, 
Inc., Knoxville, TN.   
3.5 Experimental 
 3-O-tert-butyldiphenylsilyloxy – 4 – methoxy-benzaldehyde (7) 
 Imidazole (9.5 g, 132 mmol) was added to a heterogeneous mixture of 
isovanillin (6, 10 g, 65.7 mmol) in DCM at rt.  The now homogeneous mixture 
was stirred for 5 mins and tert-butyldiphenylsilane (19.9 g, 72.3 mmol) was 
added.  The mixture was left to stir for 18 hrs, and the reaction was terminated by 
the addition of water (50 mL) and extracted into DCM (50 mL).  The organic 
layer was washed with 1 M HCl (50 mL), the phases separated and the organic 
layer washed with water (50  mL).  The organic extract was dried, filtered and 
concentrated to yield a white solid (7, quantitative yield): 
1
HNMR (300 MHz, 
CDCl3) s, C(CH3)3), 3.54 (s, OCH3), 6.79 (d, ArH, J = 8.4Hz), 7.27 (d, 
ArH, J = 1.8Hz), 7.37 (m, 7ArH), 7.68 (m, 4ArH), 9.65 (s, C(O)H). 
3-O-tert-butyldiphenylsilyloxy-4-methoxy-benzyl alcohol (8) 
 Sodium borohydride (1.5 g, 39.7 mmol) was added to a solution of 
aldehyde (7) (12.8 g, 32.8 mmol) in EtOH (50 mL).  The mixture was stirred for 
18 hrs.  The reaction was terminated by the addition of water (30 mL) and 
extracted into EtOAc (3 x 25 mL).  The combined organic extracts were dried, 
filtered and concentrated to yield a colorless oil (8, quantitative yield): 
1
HNMR 
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(300 MHz, CDCl3) 1.11 (s, C(CH3)3), 3.51 (s, OCH3), 4.39 (s, CH2), 6.72 (d, 
ArH, J = 4.2Hz), 6.73 (d, ArH, J = 1.5), 6.82 (dd, ArH,, J = 8.4, 2.1 ), 7.37 (m, 
6ArH), 7.70 (m, 4ArH). 
3-O-tert-butyldiphenylsilyloxy-4-methoxy-benzyltriphenylphosphonium 
bromide (9) 
 Phosphorous tribromide (2.02 mL, 21.3 mmol) was added to a solution of 
alcohol  (8, 15.8 g, 40.3 mmol) in DCM (250 mL).  The mixture was left to stir 
for 1 hr and the reaction was terminated with 10% NaHCO3 solution (200 mL), 
washed with water (75 mL) and extracted into DCM (3 x 75 mL).  The combined 
organic layers were dried, filtered, and concentrated.  Triphenylphosphine (0.634 
g, 2.4mmol) was added to the resulting bromide in toluene (20 mL).  The reaction 
mixture was placed in an oil bath and allowed to react under reflux at 120
o
C for 1 
hr.  The heat source was removed and the reaction mixture was stirred for 18 hrs.  
The precipitate was collected and washed with toluene to yield a pure white solid 
(1.42 g, 90%):  
1
HNMR (300 MHz, CDCl3)  0.98 (s, C(CH3)3), 3.46 (s, OCH3), 
5.02 (d, Jpch
2 
= 5.7Hz), 6.33 (t, J = 2.4Hz), 6.47 (d, J = 7.8Hz), 6.79 (dt, J = 2.4, 
8.1Hz).     
3,5-diiodo-4-methoxybenzaldehyde (11) 
 Sodium hydride (0.48g, 20 mmol, 60% dispersion in mineral oil) was 
slowly added to a cooled (0
o
C) solution of 3,5-diiodo-4-hydroxybenzaldehyde 
(10, 5g, 13.37 mmol) in anhydrous DMF (50 mL).  Iodomethane (3.33 ml, 53.5 
mmol) was added, and stirring was continued at rt in the dark for 18 hrs.  The 
reaction was terminated by the addition of water (50 mL), and the reaction 
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mixture was extracted with EtOAc-hexane (1:1, 3 x 50 mL).  The combined 
organic extract was dried, filtered and concentrated.  The residue was separated 
by column chromatography on silica gel using EtOAc-hexane (1:9) as eluent.  
The product was a white solid (11, 4.4g, 85%): mp 118-120
o
C, (lit
12
 mp 124
o
C).  
1
H-NMR (300 MHz, CDCl3)  3.91 (s, OCH3), 8.25 (s, 2ArH), 9.79 (s, CHO).    
3,5-diiodo-4,4’-dimethoxy-3’-O-tert-butyl-diphenylsilyl-Z-stilbene (12a) and 
3,5-diiodo-4,4’-dimethoxy-3’-O-tert-butyl-diphenylsilyl-E-stilbene (12b) 
 Phosphonium bromide 9 (0.624 g, 0.867 mmol) was 
dissolved in DCM at 0
o
C.  Sodium hydride (0.042 g, 1.75 mmol, 60% dispersion 
in mineral oil) was slowly added and the mixture gradually turned orange.  The 
mixture was stirred for 20 mins.  Aldehyde 11 (0.222 g, 0.572 mmol) was added 
and the mixture was stirred for 20 hrs.  The reaction was terminated by adding 
water (20 mL) and extracted with DCM (3 x 20 mL).  The organic extract was 
dried, filtered and concentrated.  The oily residue was subjected to flash 
chromatography on silica gel using EtOAc-hexane (1:20) as eluent to give an 
isomeric mixture of the title compounds (96% yield, 0.41 g): Z-isomer (12a) 
1
H-
NMR (300 MHz, CDCl3) 3.85 (s, OCH3), 3.89 (s, OCH3), 5.54 (s, OH), 6.26 
(d, J = 12Hz, ArH), 6.49 (d, J = 12Hz, ArH), 6.74 (s, ArH), 6.82 (s, ArH), 7.67 (s, 
ArH). 
E-isomer (12b) 
1
H-NMR (300 MHz, CDCl3)  3.86 (s, OCH3), 3.91 (s, OCH3), 
5.62 (s, OH), 6.71 (d, J = 16.5Hz, ArH), 6.83 (d, J = 8.1Hz, ArH), 6.90 (d, J = 
17.1Hz, ArH), 6.95 (d, J = 8.4Hz, ArH), 7.10 (d, J = 2.4Hz, ArH), 7.85 (s, 
2ArH).    
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3,5-diiodo-4,4’-dimethoxy-3’-hydroxy-Z-stilbene (13a) and 3,5-diiodo-4,4’-
dimethoxy-3’-hydroxy-E-stilbene (13b) 
 Tetrabutylammonium flouride (11.2 g, 11.2 mmol) was added to a 
solution of silyl ether 12a/12b (7.55 g, 10.1 mmol) in THF (70 mL).  The mixture 
was stirred under Ar in the dark for 20 min, and the reaction was terminated by 
the addition of water (70 mL).  The product was extracted with EtOAc (3 x 75 
mL), and the organic phase was dried, filtered and concentrated.  The crude 
product was separated by silica gel column chromatography using 1:5 EtOAc-
hexane as eluent to give stilbene 13a as an oil (1.14 g, 22%): 
1
H-NMR (300 MHz, 
CDCl3)  3.84 (s, OCH3), 3.88 (s, OCH3), 5.59 (s, OH), 6.26 (d, J = 12Hz), 6.49 
(d, J = 12Hz), 6.74 (s, 2ArH), 6.82 (s, ArH), 7.65 (s, 2ArH). 
 Further elution led to the E-stilbene 13b (3.05 g, 59%) as a yellow solid; 
1
H-NMR (300 MHz, CDCl33.86 (s, OCH3), 3.91 (s, OCH3), 5.65 ( s, OH), 
6.71 (d, ArH, J = 16Hz), 6.83 (d, ArH, J = 8.7Hz), 6.93 (d, ArH, J = 2.4 Hz), 6.96 
(d, ArH, J = 2.4Hz), 7.10 (d, ArH, J = 1.8Hz), 7.85 (s, 2ArH).  
 Dibenzyl 3,5-diiodo-4,4’-dimethoxy-Z-stilbene 3’-O-phosphate (14) 
 A solution of cis-stilbene 13a (0.372 g, 0.732 mmol) in acetonitrile (10 
mL) was cooled to -10
o
C.  Carbon tetrachloride (0.71 mL, 7.32 mmol) was added, 
and the mixture was stirred for 10min at -10
o
C in the dark.  
Diisopropylethylamine (255 uL, 1.46 mmol), and DMAP (0.089 g, 0.073 mmol) 
were added in rapid succession.  After 1 min, dibenzylphosphite (194 uL, 0.878 
mmol) was added, and the mixture was stirred for 1 hr at -10
o
C.  The reaction was 
terminated by the addition of 0.5 M KH2PO4 (10 mL) and extracted into EtOAc 
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(3 x 20 mL).  The organic phase was dried, filtered and concentrated.  The oily 
residue was separated by silica gel column chromatography using EtOAc-hexane 
1:9 (1000 mL) and EtOAc-hexane 1:4 (2600 mL) as eluent to yield 0.39g, 69% of 
a pure oil (14): bp dec. 220
o
C; Rf 0.57 (1:1 EtOAc-hexane);  
1
H-NMR (300 MHz, 
CDCl3)  3.78 (s, OCH3), 3.81 (s, OCH3), 5.13 (s, CH2), 5.16 (s, CH2), 6.28 (d, 
ArH, J = 12Hz), 6.42 (d, ArH, J = 12Hz), 6.78 (d, ArH, J = 8.7Hz), 7.00 (d, ArH, 
J = 8.7Hz), 7.07 (s, ArH), 7.33 (s, 10ArH), 7.64 (s, 2ArH).  
Sodium 3,5-diiodo-4,4’-dimethoxy-Z-stilbene 3’-O-phosphate (15) 
 Trimethylbromosilane (604 uL, 4.58 mmol) was added to a cooled (0
o
C) 
solution of phosphate 14 in DCM (120 mL).  After stirring for 45 min, the 
reaction was terminated with water (25 mL) and extracted into EtOAc (3 x 20 
mL).  The combined organic extracts were dried, filtered and concentrated to 
afford the phosphoric acid intermediate as a brown oil.  After drying (high 
vacuum) over night, the oil was dissolved in EtOH (25 mL) and NaOMe (0.248 g, 
4.6 mmol) was added.  The mixture was stirred for 1 hr, and the precipitate was 
collected and washed with minimal EtOH to afford the sodium salt as a pure 
white powder (15, 0.835 g, 63%): mp 172
o
C; 
1
H-NMR (500 MHz, CDCl3) 3.49 
(s, OCH3), 3.89 (s, OCH3), 6.27 (d, ArH, J = 5.7Hz), 6.50 (d, ArH, J = 7.2Hz), 
6.74 (s, 2ArH), 7.05 (s, ArH), 7.47 (s, ArH), 7.66 (s, ArH). 
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Chapter 4 
 
Iodination of Piperonal 
 
4.1 Introduction 
 Combretastatin A-2 (CA2, Figure 4.1) is one of the original potent tubulin 
polymerization inhibitors, human cancer cell line inhibitors, and effective 
vascular targeting stilbenes
1, 2
 isolated from the South African bush willow 
Combretum caffrum.
3
  Due to the success of the CA-2 phosphate prodrug
4, 5
 
(Figure 4.2) many modifications have been synthesized based on CA-2.
6
  In order 
to enhance the activity and better understand the structure activity relationships, 
synthesis of mono-iodo (Figure 4.3) and diiodo (Figure 4.4) derivatives were 
attempted herein, the phosphate prodrugs (Figure 4.5, 4.6) being the eventual 
targets.  The initial step, iodination of piperonal (Figure 4.7), in this scheme 
presented some challenges due to its novelty and therefore will be discussed in 
detail. 
             
Figure 4.1 Combretastatin A-2  Figure 4.2 CA2 Phosphate prodrug; z
+
=Na, Li, K 
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Figure 4.3 Mono-iodo derivative of CA-2 Figure 4.4 Diiodo derivative of CA-2 
              
Figure 4.5 Mono-iodo CA-2 prodrug          Figure 4.6 Diiodo derivative prodrug 
  Z
+
 = Li, Na, K     Z
+
 = Li, Na, K 
 
Figure 4.7 Piperonal 
4.2 Solvent Directed Electrophilic Aromatic Substitution 
 A cost effective, mild and efficient, selective iodination of piperonal (20) 
was sought in order to obtain the mono- and diiodo derivatives of CA2.  One 
promising research report reported selective iodination utilizing iodine in the 
presence of poly(4-vinylpyridine)-supported peroxodisulfate.
7
  This was a two-
step reaction: one to create the polymer, poly(4-vinylpyridine)-supported 
peroxodisulfate, and another to iodinate piperonal utilizing the polymer support.  
The supported polymer was created using very mild conditions culminating in an 
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efficient yield (98%).  The iodination with the polymer reagent was also 
performed under mild conditions, however, no product was iodinated.  Other 
iodination experiments were pursued. 
 Another promising, in fact the most promising, method employed the use 
of I2 and [bis(trifluoroacetoxy]iodo) benzene (BTI, Figure 4.8) in either 
acetonitrile or methanol to iodinate activated alkyl aryl ketones.
8
   
 
Figure 4.8 [Bis(trifluoroacetoxy)iodo] benzene (BTI) 
Iodination of piperonal (20) was first attempted utilizing I2 and BTI in acetonitrile 
and was successful in iodination.  
1
H-NMR showed about a 53% conversion to 
the desired mono-iodo product (21) and 28% percent conversion to the desired 
diiodo product (22).  Undesired iodinated products were also present in small 
amounts.  Iodination of piperonal also attempted utilizing the aforementioned 
reagents and methanol as a solvent.  Iodination appeared successful, but none of 
the desired compounds were attained.  The same reaction was also attempted 
utilizing carbon tetrachloride as the solvent, however, no reaction occurred. 
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4.3 Attempts to Drive the Reaction towards the Mono-iodo Product (21) and 
the Diiodinated Product (22) 
 Even though iodination with I2 and BTI was successful, it quickly became 
apparent that the products were not going to be easy to separate.  In an attempt to 
drive the reaction to produce more favorable yields of exclusively mono-iodinated 
and exclusively diiodinated piperonal, so that separation might be efficiently 
achieved, the reaction conditions were altered and the results observed.   
 The reaction conditions that yielded favorable yields of mono-iodinated 
piperonal as reported above will be described first.  The first scheme (scheme 4.1) 
included one equivalent of piperonal, 0.6 equivalents of I2, 1.2 equivalents of BTI, 
and acetonitrile as solvent at room temperature.  The reaction led to a 53% 
conversion of piperonal to the mono-iodinated product (21), 28% to the 
diiodinated product (22), and 18% of undesired products.  Another set of reaction 
conditions that produced a favorable yield of mono-iodinated piperonal included 
one equivalent of piperonal, 0.6 equivalents of I2, two equivalents of BTI, and 
acetonitrile as solvent at room temperature.  These reaction conditions resulted in 
a 59% conversion of piperonal to the mono-iodinated product (21), 17% 
conversion to the diiodo product (22), and 24% of other products.  The final set of 
reaction conditions that produced a favorable yield of mono-iodinated piperonal 
comprised one equivalent of piperonal, one equivalent of I2, two and a half 
equivalents of BTI, and acetonitrile as solvent at 50
o
C.  These reaction conditions 
resulted in a 59% conversion of piperonal to the mono-iodinated product (21), a 
13% conversion to the diiodinated product (22), and 28% of other products.   
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 While the yield of mono-iodinated product (21) produced was favorable 
with the preceding methods, the amount of side products produced was 
unfavorable.  Separation of the iodinated products was attempted utilizing many 
solvent systems in both flash and gravity silica, but to no real consequence.  In an 
attempt to gain pure compounds at some point of the reaction sequence, the 
reaction was carried forward and separation attempted at each step.  Separation 
was no easier at any step of the reaction sequence and so it is apparent that 
extensive HPLC methods are needed for this type of separation. 
 The reaction conditions that favored the production of the desired 
diiodinated product (22) include three different techniques.  The first scheme was 
composed of one equivalent of piperonal, 1.8 equivalents of I2, 3.4 equivalents of 
BTI, and acetonitrile as solvent at room temperature.  These reaction conditions 
resulted in a 40% conversion of piperonal to the diiodo product (22), 37% 
conversion to the mono-iodo product (21), and 20% of other products.  The 
second reaction scheme that favored the diiodinated product (22) began with one 
equivalent of piperonal, 0.6 equivalents of I2, 1.2 equivalents of BTI, and 
acetonitrile at room temperature.  The reaction was monitored by TLC and driven 
to completion by continuously adding I2 and BTI until no starting material was 
present.  This resulted in the addition of 1.7 equivalents of I2 and 2.4 equivalents 
of BTI which consumed all the starting material and provided 54% conversion of 
piperonal to the diiodo product, 17% conversion to the mono-iodo product, and 
18% of other products.  Furthermore, there was an excess of I2 in the reaction 
mixture that had to be dispelled with Na2S2O5.  The final reaction scheme 
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included one equivalent of piperonal, one equivalent of I2, two equivalents of 
BTI, and acetonitrile as solvent at 50
o
C.  This composition led to a 44% 
conversion of piperonal to the diiodo product (22), a 32% conversion to the 
mono-iodo product (21), and 25% of other products.      
 Elevating the temperature with less BTI than a reaction at room 
temperature seemed to force the reaction towards a diiodinated product.  A 
reaction involving several equivalents of BTI with an elevated reaction 
temperature has yet to be performed, but would seem to favor the diiodinated 
product (22).  As stated earlier, even though the reaction conditions could be 
altered to favor the diiodinated product (22), the existence of other iodinated 
products made separation impractical.  Extensive HPLC techniques are needed for 
the separation of these iodinated products.     
 Interestingly, a reaction run utilizing methanol as a solvent produced 
entirely undesired iodinated products.  While the structure(s) of these other 
products were not confirmed, mass spec and 
1
H-NMR revealed that one is another 
diiodinated product (Figure 4.9) (23).   
 
Figure 4.11 2,3-Diiodo Piperonal 
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4.4 Summary 
 The success of the combretastatins including combretastatin A-2 led to 
this SAR study which led to a cost effective and mild reaction to iodinate 
piperonal.  This reaction was manipulated to drive the reaction to favor mono-
iodination or diiodination.  Unfortunately, efficient separation of the mono- (21) 
and diiodo (22) products from each other as well as from other products was not 
achieved.  Extensive HPLC appeared needed for this endeavor.  Hopefully, based 
on the preceding experiments, an even more efficient and reactive method can be 
achieved.  
4.5 Experimental 
General Mono-iodination Procedures 
Method A: BTI (0.516 g, 1.2 mmol) was added to a solution of piperonal (20) 
(0.15 g, 1 mmol) and iodine (0.15 g, 0.6 mmol) in acetonitrile (5 mL).  The 
mixture was stirred for 2 hrs and the reaction terminated by addition of (0.1 M) 
NaOH and extracted into DCM (3 x 5 mL).  The combined organic layers were 
dried, filtered and concentrated to yield a reddish orange solid (0.43 g crude).  
1
H-
NMR revealed 59% mono-iodinated product (21), 32% diiodinated product (22), 
and 8% other products (23).   
 Method B:  (This reaction was monitored by TLC using EtOAc-hexane 
1:8 as eluent)  BTI (0.142 g, 0.33 mmol) was added to a solution of piperonal (20, 
0.1 g, 0.67 mmol) and iodine (0.1 g, 0.4 mmol) in acetonitrile (5 mL).  The 
reaction mixture was stirred for 30 min, BTI (0.142 g, 0.33 mmol) was added; 
after stirring for 45 min BTI (0.142 g, 0.33 mmol) was added; following another 
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3.5 hrs BTI (0.142 g, 0.33 mmol) was again added.  The reaction was stirred for 
18 hrs, terminated by the addition of (0.1 M) NaOH (until pH7) and the product 
extracted into DCM (4 x 25 mL).  The combined organic layers were dried, 
filtered and concentrated to yield a reddish orange oil (0.175 g crude).  
1
H-NMR 
revealed 59% mono-iodinated product (21), 17% diiodinated product (22), and 
24% other products (23).   
 Method C:  BTI (0.361 g, 0.84 mmol) was added to a heated (50
o
C) 
solution of piperonal (20) (0.1 g, 0.67 mmol) and iodine (0.178 g, 0.7 mmol) in 
acetonitrile (6 mL).  The reaction mixture was stirred for 2 hrs at which time TLC 
revealed a significant amount of starting material remained.  Another 0.84 mmol’s 
of BTI was added and the mixture was stirred for another 2 hrs.  The solvent was 
removed invacuo to yield a reddish brown solid.  
1
H-NMR revealed 57% mono-
iodinated product (21), 13% diiodinated product (22), and 31% other products 
(23).     
General Diiodination Procedures 
 Method A: BTI (1.5 g, 3.4 mmol) was added to a solution of piperonal 
(20, 0.15 g, 1 mmol) and iodine (0.45 g, 0.1.8 mmol) in acetonitrile (7 mL).  The 
mixture was stirred for 2 hrs and the reaction terminated by addition of (0.1 M) 
NaOH (until pH 7) and extracted into DCM (3 x 15 mL).  The combined organic 
layers were dried, filtered and concentrated to yield a reddish orange solid (0.35 g, 
crude).  
1
H-NMR revealed 40% conversion to the diiodo product (22) and 37% 
conversion to the mono-iodo product (21).   
 Method B: BTI (3.6 g, 8.37 mmol) was added to a solution of piperonal 
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(20, 1.05 g, 6.98 mmol) and iodine (1.07 g, 4.2 mmol) in acetonitrile (100 mL) at 
room temperature.  The reaction mixture was stirred for 2 hrs, more iodine (0.7g, 
2.8 mmol) was added and the mixture was stirred for 12 hrs.  Additional BTI 
(0.27g, 0.63 mmol) was added and the reaction was left to stir for 2 hrs.  At this 
point another equivalent of BTI (0.27g, 0.63 mmol) was added.  After one hour 
the reaction had not yet reached completion so more iodine (0.77g, 3.0 mmol) and 
BTI (0.73g, 1.7 mmol) were added to the solution and the reaction mixture was 
stirred overnight.  After 12 hrs, the reaction had not yet reached completion so 
more iodine (1.5g, 6.0 mmol) and BTI (3.4g, 8.0 mmol) were added.  After 1.5 
hours TLC revealed that conversion of starting material and mono-iodo to diiodo 
was partially successful.  In an attempt to reach full conversion of mono-iodo to 
diiodo more iodine (0.75g, 3.0 mmol) and BTI (1.7g, 4.0 mmol) were added and 
stirring continued for 2 hrs.  An excess of iodine was present in the reaction 
mixture so more BTI (0.85g, 2.0 mmol) was added and stirring continued another 
2 hrs.  The reaction was terminated with (0.1M) NaOH (until pH 1), the product 
extracted into DCM (3 x 100mL), dried, filtered, and concentrated to yield a dark 
purple liquid.  Saturated Na2S2O5 was added to the liquid to remove excess iodine.  
The remaining organic layer was a reddish-orange color (1.94g crude).  
1
H-NMR 
revealed 54% conversion to diiodo product (22), 18% other products, and 17% 
mono-iodo product (21).    
 Method C: BTI (28.7g, 66.6 mmol) was added to a solution of piperonal 
(20, 5g, 33.3 mmol) and iodine (8.5g, 33.3 mmol) in acetonitrile at 50
o
C.  In 2 hrs 
the reaction was finished and the product concentrated (invacuo) to yield a deep 
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reddish brown solid.  The product was placed in EtOAc and the solvent filtered to 
yield a grayish green solid (6.0g crude).  
1
H-NMR revealed 44% conversion to 
diiodo product (22), 32% to mono-iodo product (21), and 25% other products.        
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Chapter 5 
 
Partial Synthesis and Biological Evaluation of the Antineoplastic Agent 5-
iodo-3,4-methylenedioxy-2’,3’-dihydroxy-4’-methoxy-Z-stilbene (16) and 2,5-
diiodo-3,4-methylenedioxy-2’,3’-dihydroxy-4’-methoxy-Z-stilbene (17) 
 
5.1 Introduction 
 Since complete separation of the iodinated piperonal was not achieved the 
synthesis began with mono and diiodo piperonal mixtures that led to several 
products at each step.  However, prior to the wittig step, separation was almost 
complete and characterization was achieved at this point for both 5-iodo-3,4-
methylenedioxy-2’,3’-dihydroxy-4’-methoxy-Z-stilbene (16) and 2,5-diiodo-3,4-
methylenedioxy-2’,3’-dihydroxy-4’-methoxystilbene (17). 
5.2 Results and Discussion 
 The A-rings, starting with either pure 5-iodo-piperanol (21) or 2,5-diiodo-
piperanol (22) were obtained employing a solvent directed electrophilic aromatic 
substitution with BTI (Figure 4.8) as the key reagent.  Many chromatographic 
column separations had to be employed in order to obtain a very small amount of 
each pure product for characterization.  Since these are new compounds, they 
were tested against a panel of human cancer lines at this early point in the 
synthetic scheme (Table 5.1). 
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    Table 5.1 Cancer Cell Biology for 5-iodo-piperonal (21) and 2,5-diiodo-
piperonal (22)   
 
Compound BXPC-3 MCF-7 SF-268 NCI-H460 KM20L2 DU-145 
83F4 
(mostly 21, 
22, 23) 
>10 3.1 5.6 29.9 >10 15.1 
111F5-6 
(21) 
>10 >10 >10 >10 >10 >10 
91F1 (21, 
mostly 22, 
23)  
2.3 2.3 2.8 3.5 >10 3.4 
111F2 (22) >10 4.9 4.7 6.3 >10 >10 
83F3 (23) >10 3.3 2.1 7.0 >10 5.7 
 
 The inhibitory properties for either of the mono-iodo samples is not ideal; 
however, it is interesting to note that the less pure sample (83F4) has increased 
inhibitory properties over the pure mono-iodo-piperonal (21).  The diiodo 
piperonal (22) was more inhibitory in general than the mono-iodo piperonal (21).  
Similarly to the mono-iodo piperonal, the diiodo sample that was not pure 
exhibited more inhibition than the pure sample.  Furthermore, the undesired 
diiodo piperonal (23) exhibited more inhibition than expected. 
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 The alcohols (24), (26) and the phosphonium bromides (25), (27) were 
synthesized utilizing standard reduction, bromination, and SN2 procedures.  
Combustion and spectral analyses confirmed each of their structures.   
     
Scheme 5.1 Mono-iodination of Piperonal, Reduction, Bromination and 
 Conversion to Phosphonium Bromide 25 
  
Scheme 5.2 Diiodination of Piperonal, Reduction and Conversion to 
 Phosphonium Bromide 27 
 The B-ring, starting with 2,3 dihydroxy-4-methoxy benzaldehyde, was 
synthesized utilizing a demethylation procedure.  That was followed by a 
protection with TBDMS to produce the B-ring 2,3-Bis-[tert-butyldimethylsiloxy]-
4-methoxy-benzaldehyde (29). 
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Scheme 5.3  Synthesis of the Protected B-ring 29 
 Due to time constraints, the key precursor of 5-mono-iodo-4’-methoxy-
3,4-methylenedioxy-2’,3’-dihydroxy-Z-stilbene (16) was not obtained in pure 
form.  However it was synthesized utilizing a Wittig reaction sequence and 
subsequent deprotection to yield a Z/E mixture (Scheme 5.4).  Despite the lack of 
separation, the Z/E mixture was tested against several human cancer cell lines and 
the findings summarized in Table 5.2.  Again, activity is not ideal but the results 
are promising.   
 
Scheme 5.4 Synthesis of 4,5-Bismethyl-3-iodo-CA-2 16 
 The same time constraints that restricted the separation of the mono-iodo 
stilbene (16) also restricted the separation of 2,5-diiodo-3,4-methylenedioxy-
2’,3’-dihydroxy-Z-stilbene (17) from it E-isomer.  The diiodo-stilbenes were also 
synthesized utilizing the same Wittig reaction sequence and subsequent 
deprotection (Scheme 5.5).  The protected Z/E mixture was tested against several 
human cancer cell lines and the findings summarized in Table 5.2.  The results are 
very useful as they emphasize the pronounced reduction in cancer cell growth 
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inhibition when progressing from the fluoro-combretastatins to these iodo-
combretastatins.   
Scheme 5.5 Synthesis of 3,4-Bismethyl-2,5-diiodo-CA-2 17 
Table 5.2 Cancer Cell Biology for 5-mono-iodo-4’-methoxy-3,4-methylenedioxy-
2’,3’-dihydroxy-stilbenes and 2,5-diiodo-4’-methoxy-3,4-methylendioxy-2’,3’-O-
tert-butyl-dimethylsilyl-stilbenes 
 
Compound BXPC-3 MCF-7 MCF-10A NCI-H460 SF268 DU-145 
149C (mostly 
Z 16, E 16) 
>10 5.1 4.7 31.4 15.3 >10 
145f2 (mostly 
30, 31) 
>10 >10 >10 >10 >10 >10 
 
5.3 Conclusions 
 With the exception of the synthesis of novel compounds 21 and 22, the 
reaction sequence followed our general synthetic approach to the combretastatin 
class of stilbenes.
1
 The results of the biological evaluations for the iodo/diiodo 
mixtures suggest future separation of the stilbenes (16) and (17) will lead to pure 
specimens with only modest cancer cell growth inhibition.  However, the pure 
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stilbenes might have important anticancer activity when used against in-vivo 
thyroid cancer.  2,3-Diiodo piperonal (23) should be synthesized to provide its Z-
stilbene and corresponding phosphate pro-drug in order to further evaluate it 
against human cancer and especially against thyroid cancer.   
5.4 Materials and Methods 
 Anhydrous dicholoromethane (DCM), anhydrous toluene, dibenzyl 
phosphite, triphenylphosphine, and carbon tetrachloride were obtained from 
Sigma-Aldrich Chemical Company (Milwaukee, WI).  Diisopropylethylamine 
was obtained from Avocado Alfa Aesar (Ward Hill, MA).  All other reagents 
were purchased from Acros Organics (Fisher Scientific, Pittsburg, PA).   
 All reactions were monitored by thin-layer chromatography using 
Analtech silica gel GHLF Uniplates visualized under long-wave and short-wave 
UV irradiation and by dipping into phosphomolybic acid in ethanol followed by 
heating.  Solvent extracts of aqueous solutions were dried over anhydrous 
magnesium sulfate.  Where appropriate, the crude products were separated by 
column chromatography, flash (230-400 mesh ASTM) or gravity (70-230 mesh 
ASTM) silica from E. Merck. 
 Melting points were measured using an electrothermal digital melting 
point apparatus and are uncorrected.  All 1H- and 13C-NMR spectra were 
obtained using Varian Gemini 300 MHz or varian unity 400 or 500 MHz 
instruments with CDCl3 (tetramethylsilane internal reference) as solvent unless 
otherwise noted.  Elemental analyses were determined by Galbraith Laboratories, 
Inc., Knoxville, TN.   
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5.5 Experimental 
2,3-dihydroxy-4-methoxy-benzaldehyde (28) 
 Preparation of benzaldehyde 28 was repeated essentially as described 
(Pettit et al., 2000)
2
 from 2,3,4-trimethoxybenzaldehyde (5 g) to yield a yellow 
solid which was recrystallized to afford yellow needles 28 (2.32 g, 54%): m.p. 
115-116
o
C [lit. 116-117
o
C (Pettit et al., 1987)
3
]; (1:1 EtOAc-hexane); 
1
HNMR 
(300 MHz, CDCl3)  3.99 (s, 3H, OCH3), 5.46 (s, 1H, OH), 6.62 (d, 1H, J = 8.4 
Hz, ArH), 7.15 (d, 1H, J = 8.4 Hz, ArH) 9.76 (s, 1H, CHO), 11.12 (s, 1H, OH). 
2,3-Bis-[tert-butyldimethylsiloxy]-4-methoxybenzaldehyde (29) 
 Preparation of silyl ether 29 was repeated essentially as originally 
described (Pettit et al., 1987)
3
 from diphenol 28 (2.2 g).  The reaction yielded a 
brown solid which was recrystallized from methanol to yield a white solid 29 
(3.46 g, 67%); m.p. 73-74
o
C [lit. 74.5-76
o
C (Pettet et al., 1987)
3
]; Rf 0.77 (1:1 
EtOAc-hexane); 
1
HNMR (300 MHz, CDCl3) 0.14 (s, 12H, 4 x SiCH3), 0.99 (s, 
9H, 3 x CH3), 1.04 (s, 9H, 3 x CH3), 3.84 (s, 3H, OCH3), 6.63 (d, 1H, J = 8.7 Hz, 
ArH), 7.49 (d, 1H, J = 8.7 Hz, ArH), 10.23 (s, 1H, CHO).  HRMS calcd. for 
C20H36O4Si2 [M+H]
+
 397.22305, found 397.2030. 
5-iodo-3,4-methylenedioxybenzaldehyde (21)  
 The product was separated by silica gel column chromatography using 
EtOAc-hexane 1:4 as eluent resulting in a cream solid 21 (359 mg, 19%): Rf 0.23 
(1:8 EtOAc-hexane as eluent); 
1
HNMR (300 MHz, CDCl3) 6.15 (2H, s, -
OCH2O-), 7.27 (1H, s, ArH), 7.69 (1H, s, ArH), 9.75 (1H, s, -CHO); 
1
HNMR 
(500 MHz, CDCl3)s, -CH2-), 7.27 (1H, s, ArH), 7.70 (1H, s, ArH) 
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9.75 (1H, s, -CHO); 
13
CNMR (500 MHz, CDCl3)  70.12, 101.73, 106.88, 
133.40, 135.29, 136.50, 147.47, 188.94; HRMS calcd. for C8H5IO3 [M+H]
+
 
276.9362, found 276.9360. 
5-iodo-3,4-methylenedioxy-benzyl alcohol (24)  
 NaBH4 (2.45 g, 64.8 mmol) was added to a mixture of mono-iodo 21 and 
diiodo 22 aldehydes (14.91 g, 54 mmol) in ethanol (200 mL) and the reaction was 
left to stir for 23 hrs.  The reaction was terminated by the addition of solid 
NaHCO3, filtered and the solvent removed in vacuo to yield a cream solid. The 
products (1.0 g) were separated by flash silica gel column chromatography using 
½% MeOH-DCM as eluent.  The iodo alcohol resulted in a white solid: mp 
161
o
C; 
1
HNMR (300 MHz, CDCl3) 4.57 (2H, s, -CH2-), 4.76 (1H, s, -OH), 6.02 
(s, 2H, -OCH2O-), 6.80 (1H, s, ArH), 7.13 (1H, s, ArH);
 1
HNMR (500 MHz, 
CDCl3)  4.56 (2H, s, -CH2-), 4.72 (1H, s, -OH), 6.02 (1H, s, -OCH2O-), 6.81 
(1H, s, ArH), 7.14 (1H, s, ArH);  
13
CNMR (500 MHz, CDCl3) 64.65, 70.49, 
100.87, 101.41, 107.83, 108.68, 128.86, 136.98.  Analysis calcd. for C8H7IO3: I, 
45.64. Found: I, 46.19.    
5-iodo-3,4-methylenedioxy-benzyl-triphyphenylphosphonium bromide (25)  
 Phosphorous tribromide (32.4 uL, 0.342 mmol) was added to a solution of 
iodo alcohol 24 (0.095 g, 0.342 mmol) in DCM (14 mL) and the reaction was 
stirred for 40 min.  The reaction was terminated with 10% NaHCO3 solution (2 x 
50 mL), extracted into DCM (1 x 50 mL), the combined organic layers washed 
with water (1 x 50 mL), and the aqueous layer extracted with DCM (3 x 50 mL).  
The combined organic layers were dried, filtered and concentrated to yield a 
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white solid (0.227 g, 88.5%).  Triphenylphosphine (0.192 g, 0.732 mmol) was 
added to a solution of the bromide (0.227g, 0.666 mmol) in toluene (10 mL) the 
reaction mixture heated at reflux for 1 hr.  The reaction was then stirred at room 
temperature for 16 hrs.  The product was collected and washed with toluene to 
yield a purple solid 25 (0.217 g, 54%): mp 195-242
o
C (dec);  
1
HNMR (500 MHz, 
CDCl 5.48 (2H, d, J = 14 Hz, -CH2-), 5.94 (2H, s, -OCH2O-), 6.56 (1H, s, 
ArH), 6.81 (1H, s, ArH), 7.67 (6H, s, ArH) 7.80 (9H, m, ArH);
 13
CNMR 
MHz,CDCl3)31.18, 70.22, 101.17, 112.11,  112.14, 117.58, 118.26, 122.69, 
122.76, 130.34, 130.44, 133.32, 133.37, 134.65, 134.73, 134.76, 135.24, 135.27, 
146.74, 149.67.  Analysis calcd. for C26H21IBrO2P: C, 51.77; H, 3.51. Found: C, 
50.08; H, 3.40. 
5-iodo-4’-methoxy-3,4-methylenedioxy-2’,3’-dihydroxy-Z-stilbene (16)  
 n-Butyl lithium (0.84 mL, 1.328 mmol) was added to a cooled (-25
o
C) 
heterogeneous solution of phosphonium bromide 25 (0.2 g, 0.332 mmol) in THF 
(10 mL).  The reaction was stirred for 20 min and aldehyde 29 (0.132 g, 0.332 
mmol) was added.  After 1 hr, the reaction temp was allowed to rise to rt and the 
reaction was stirred for another 18 hrs.  The reaction was terminated by the 
addition of water (25 mL) and extracted into EtOAc (3 x 25 mL).  The combined 
organic layers were dried, filtered and concentrated to yield the crude silyl ether.  
Tetrabutylammonium flouride (1.3 mL, 1.3 mmol) was added to a solution of 
crude silyl ether (0.374 g, 0.583 mmol) in THF (10 mL).  The mixture was stirred 
under Ar in the dark for 1.5 hrs, and the reaction was terminated by the addition 
of water (10 mL).  The product was extracted with EtOAc (3 x 15 mL), and the 
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organic phase was dried, filtered and concentrated to yield a brown oil.  
1
HNMR 
(300 MHz CDCl3) 2.85 (1H, s, OH), 3.15 (1H, s, OH), 3.83 (3H, s, OCH3), 5.90 
(2H, s, -OCH2O-), 6.34 (1H, d, J = 6 Hz), 6.51 (1H, d, J = 6.6 Hz), 6.62 (1H, d, J 
= 8.4 Hz), 6.66 (1H, ArH), 6.72 (1H, s, ArH), 7.14 (1H, d, J = 9.3 Hz). 
Synthesis of 2,5-diiodo-3,4-methylenedioxy-2’,3’-dihydroxy-4’-methoxy 
stilbene 
2,5-diiodo-3,4-methylenedioxybenzaldehyde (22) 
 The product was separated by silica gel column chromatography using 
EtOAc-hexane 1:8 as eluent resulting in a white solid: Rf 0.39 (1:8 EtOAc/hexane 
as eluent); 
1
HNMR (300 MHz CDCl3)  6.21 (2H, s, -OCH2O-), 7.80 (1H, s, 
ArH), 9.83 (1H, s, -CHO).   1HNMR (500 MHz, CDCl3)  6.21 (2H, s, -OCH2O-
), 7.80 (1H, s, ArH), 9.83 (1H, s, -CHO). 
13
CNMR (500 MHz, CDCl3)  75.78, 
101.05, 109.24, 130.09, 135.24, 148.97, 152.29, 191.55.  HRMS calcd. for 
C8H4I2O3 [M+H]
+
 402.8329, found 402.8357.   
2,5-diiodo-3,4-methylenedioxybenzyl alcohol (26) 
 NaBH4 (56.5 mg, 1.4 mmol) was added to a mixture of aldehyde 22 
(502mg, 1.2 mmol) in EtOH (5 mL) under Ar at rt.  The reaction was left to stir 
for 16 hours.  The reaction was terminated with solid NaHCO3, filtered and 
vacced down to yield a white solid (500 mg, 99% crude).  The product was 
separated by silica gel column chromatography using ½% MeOH/DCM + 2 mL 
MeOH.  The product was a white solid.  
1
HNMR (300 MHz, CDCl3)  4.59 (2H, 
s, -CH2-), 5.02 (1H, s, OH), 6.10 (2H, s, -OCH2-), 7.24 (1H, s, ArH).  
1
HNMR 
(500 MHz, CDCl3)  4.59 (2H, s, -CH2-), 5.01 (1H, s, OH), 6.10 (2H, s, -OCH2O-
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), 7.25 (1H, s, ArH).  
13
CNMR (500 MHz, CDCl3)  67.78, 74.40, 100.50, 100.80, 
130.18, 137.60, 147.69, 148.69.  Analysis calcd. for C8H6I2O3: C, 23.79; H, 1.50; 
I, 62.83. Found: C, 23.91; H, 1.55; I, 63.43. 
2,5-diiodo-3,4-methylenedioxybenzyltriphenylphosphonium bromide (27) 
 Phosphorous tri-bromide (125uL, 0.131 mmol) was added to a solution of 
alcohol 26 (97 mg, 0.262 mmol) in DCM (14 mL) under argon at room 
temperature and the reaction was left to stir for 20 hours.  The reaction was 
terminated with 10% NaHCO3 solution, extracted into DCM (3 x 10mL), dried 
(MgSO4) and concentrated to yield a white solid (100 mg crude).  
Triphenylphosphine (62 mg, 0.236 mmol) was added to a solution of the resulting 
bromide (100 mg, 0.215 mmol) in toluene (5 mL) at room temperature.  The 
reaction temperature was then elevated to react under reflux for two hours.  The 
temperature was then reduced and the reaction was left to stir for 17 hours.  The 
white precipitate was filtered to yield a white powdery solid (90 mg 57.5%): 
1
HNMR (300 MHz, CDCl3)  5.69 (2H, d, JPCH2 = 14.1 Hz, -CH2-) 6.05 (2H, s, -
OCH2O-), 7.16 (1H, d, J = 3.0 Hz, ArH), 7.68 (6H, m, ArH), 7.75 (5H, m, ArH), 
7.81 (4H, m, ArH).  
1
HNMR (500 MHz, CDCl3)  5.65 (1H, s, -CH2-), 5.68 (1H, 
s, -CH2-), 6.05 (2H, s, -OCH2O-), 7.15 (2H, d, J = 2.1 Hz, ArH), 7.67 (6H, m, 
ArH), 7.74 (6H, m, ArH), 7.82 (3H, t, J = 4.4 Hz, ArH).  
13
CNMR (500 MHz, 
CDCl3)  33.53, 71.14, 71.17, 81.49, 81.54, 100.74, 105.0, 117.20, 117.88, 
125.37, 125.44, 130.49, 130.59, 130.61, 133.81, 133.86, 134.73, 134.81, 134.83, 
135.49, 135.51, 135.55, 148.16, 148.83. Analysis calculated for C26H20I2BrO2P: 
C, 42.83; H, 2.76; I, 34.81.  Found C, 42.70; H, 2.73; I, 53.34. 
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2,5-diiodo-4’-methoxy-3,4-methylenedioxy-2’,3’-O-tert-butyl-dimethylsilyl-Z-
stilbene (30) and 2,5-diiodo-4’-methoxy-3,4-methylenedioxy-2’,3’-O-tert-
butyl-dimethylsilyl-E-stilbene (31) 
 n-Butyl lithium (3.7 mL, 2.3 mmol) was added to a cooled (-25
o
C) 
heterogeneous solution of phosphonium bromide 27 (0.84 g, 1.15 mmol) in THF 
(50 mL).  The reaction was stirred for 20 min and aldehyde 29 (0.46 g, 1.15 
mmol) was added.  After 1 hr, the reaction temp was allowed to rise to rt and the 
reaction was stirred for another 18 hrs.  The reaction was terminated by the 
addition of water (50 mL) and extracted into EtOAc (4 x 50 mL).  The combined 
organic layers were dried, filtered and concentrated to yield a brown oil (1.1 g, 
crude).  The product was separated by silica gel column chromatography using 
EtOAc-hexane 1:19 as eluent resulting in a clear oil.  Rf Z: 0.48; E: 0.41 (19:1 
EtOAc/Hexane). 
2,5-diiodo-4’-methoxy-3,4-methylenedioxy-2’,3’-dihydroxy-Z-stilbene (17)  
 TBAF (1.0 mL, 1.0 mmol) was added to a cooled, stirred solution of 
protected stilbene (30) in anhydrous THF (7.5 mL) under argon.  After 1.5 hrs. the 
reaction was terminated with H2O (15 mL) and extracted into EtOAc (4 x 12 mL).  
The combined organic layers were dried, filtered and concentrated to yield a 
brown oil (367 mg, crude).  
1
HNMR (300 MHz CDCl3)  3.82 (3H, s, OCH3), 
5.01 (1H, s, OH), 5.25 (1H, d, J = 11.4, ArH), 5.54 (1H, d, J = 17, ArH), 5.91 
(1H, s, OH), 6.07 (2H, s, -OCH2O-), 6.69  (1H, d, J = 10.8), 6.75 (1H, d, J = 10), 
6.98 (1H, s, ArH).  
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 Further separation and characterization of these products was postponed 
due to the abrupt closing of the Cancer Research Institute and loss of our research 
laboratories as well as misplacement of product materials by the moving crews.  
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